New weight-loss injection targets fat cells: CBL-514 selectively induces apoptosis of fat cells

Consensus

Well-supported — high-quality sources agree

5 sources · 5 support

What we can confirm

Clinical-trial records and a peer-reviewed Phase 2 study describe CBL-514 as an injectable treatment designed to reduce subcutaneous fat, with its stated mechanism involving selective adipocyte apoptosis. The claim is accurate as a description of the drug's reported mechanism, although CBL-514 remains investigational and is not established as an approved general weight-loss medication.

Sources

pmc.ncbi.nlm.nih.gov

supportsPeer-reviewed

ClinicalTrials.gov

clinicaltrials.gov

supportsOfficial

Caliway Announces First Patient Dosed in Global Phase 3 SUPREME-01 Trial of CBL-514; New Preclinical Data Accepted for Presentation at ObesityWeek 2026-Caliway Biopharmaceuticals Co., Ltd

caliwaybiopharma.com

supportsMedia

Caliway Announces Positive Phase 2 Results of CBL-514 in Dercum's Disease, Achieving Primary Endpoint with Statistically Significant and Sustained Pain Reduction-Caliway Biopharmaceuticals Co., Ltd

caliwaybiopharma.com

supportsMedia